A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Condition:   Recessive Dystrophic Epidermolysis Bullosa Intervention:   Biological: FCX-007 (no generic name is established; see below for FCX-007 description) Sponsors:   Fibrocell Technologies, Inc.;   Castle Creek Pharmaceuticals, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials